tiprankstipranks
Trending News
More News >
Maze Therapeutics, Inc. (MAZE)
NASDAQ:MAZE
US Market
Advertisement

Maze Therapeutics, Inc. (MAZE) Stock Forecast & Price Target

Compare
25 Followers
See the Price Targets and Ratings of:

MAZE Analyst Ratings

Strong Buy
5Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Maze
Therapeutics, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MAZE Stock 12 Month Forecast

Average Price Target

$26.75
▲(62.61%Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Maze Therapeutics, Inc. in the last 3 months. The average price target is $26.75 with a high forecast of $34.00 and a low forecast of $17.00. The average price target represents a 62.61% change from the last price of $16.45.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","35":"$35","14.75":"$14.75","21.5":"$21.5","28.25":"$28.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$26.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,14.75,21.5,28.25,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.66,13.378461538461538,15.096923076923076,16.815384615384616,18.533846153846156,20.252307692307692,21.970769230769232,23.689230769230768,25.407692307692308,27.126153846153848,28.844615384615384,30.563076923076924,32.28153846153846,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.66,12.820769230769232,13.981538461538461,15.142307692307693,16.303076923076922,17.463846153846156,18.624615384615385,19.785384615384615,20.946153846153848,22.106923076923078,23.267692307692307,24.42846153846154,25.58923076923077,{"y":26.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.66,12.070769230769232,12.481538461538461,12.892307692307693,13.303076923076922,13.713846153846154,14.124615384615385,14.535384615384615,14.946153846153846,15.356923076923078,15.767692307692307,16.17846153846154,16.58923076923077,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.23,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.9,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.59,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$34.00Average Price Target$26.75Lowest Price Target$17.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on MAZE
Ananda GhoshH.C. Wainwright
H.C. Wainwright
$34
Buy
106.69%
Upside
Initiated
07/23/25
Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued StockValuations and Risks. We assume the number of diagnosed AKD patients in the US is 142K that might be potentially treated by MZE829. We assume that MZE829 launches in the US in 2030. We project a peak penetration rate of 5% in 2035, which translates into approximately 8K patients on MZE829 in 2035. We assign a PoS of 15%. Assuming an annual cost of $130K at launch growing to $151K at 3% YoY price growth by 2035. We estimate total revenue to be around $1.2B. We estimate total probability adjusted revenue can reach $176M by 2035. For EU, we estimate a total revenue of $653M.
TD Cowen
Buy
Reiterated
07/21/25
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE) and Sarepta Therapeutics (NASDAQ: SRPT)
Wedbush
$17
Buy
3.34%
Upside
Initiated
07/08/25
Maze Therapeutics initiated with an Outperform at WedbushMaze Therapeutics initiated with an Outperform at Wedbush
Leerink Partners Analyst forecast on MAZE
Joseph SchwartzLeerink Partners
Leerink Partners
$28
Buy
70.21%
Upside
Reiterated
06/26/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
J.P. Morgan Analyst forecast on MAZE
Anupam RamaJ.P. Morgan
J.P. Morgan
$30$28
Buy
70.21%
Upside
Reiterated
05/20/25
Analysts Offer Insights on Healthcare Companies: Strata Skin Sciences (NASDAQ: SSKN), Ionis Pharmaceuticals (NASDAQ: IONS) and Maze Therapeutics, Inc. (NASDAQ: MAZE)
Guggenheim
$19
Buy
15.50%
Upside
Initiated
02/25/25
Maze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders Market
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on MAZE
Ananda GhoshH.C. Wainwright
H.C. Wainwright
$34
Buy
106.69%
Upside
Initiated
07/23/25
Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued StockValuations and Risks. We assume the number of diagnosed AKD patients in the US is 142K that might be potentially treated by MZE829. We assume that MZE829 launches in the US in 2030. We project a peak penetration rate of 5% in 2035, which translates into approximately 8K patients on MZE829 in 2035. We assign a PoS of 15%. Assuming an annual cost of $130K at launch growing to $151K at 3% YoY price growth by 2035. We estimate total revenue to be around $1.2B. We estimate total probability adjusted revenue can reach $176M by 2035. For EU, we estimate a total revenue of $653M.
TD Cowen
Buy
Reiterated
07/21/25
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE) and Sarepta Therapeutics (NASDAQ: SRPT)
Wedbush
$17
Buy
3.34%
Upside
Initiated
07/08/25
Maze Therapeutics initiated with an Outperform at WedbushMaze Therapeutics initiated with an Outperform at Wedbush
Leerink Partners Analyst forecast on MAZE
Joseph SchwartzLeerink Partners
Leerink Partners
$28
Buy
70.21%
Upside
Reiterated
06/26/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
J.P. Morgan Analyst forecast on MAZE
Anupam RamaJ.P. Morgan
J.P. Morgan
$30$28
Buy
70.21%
Upside
Reiterated
05/20/25
Analysts Offer Insights on Healthcare Companies: Strata Skin Sciences (NASDAQ: SSKN), Ionis Pharmaceuticals (NASDAQ: IONS) and Maze Therapeutics, Inc. (NASDAQ: MAZE)
Guggenheim
$19
Buy
15.50%
Upside
Initiated
02/25/25
Maze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders Market
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Maze Therapeutics, Inc.

1 Month
xxx
Success Rate
3/4 ratings generated profit
75%
Average Return
+17.00%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +17.00% per trade.
3 Months
xxx
Success Rate
3/4 ratings generated profit
75%
Average Return
+28.90%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +28.90% per trade.
1 Year
Joseph SchwartzLeerink Partners
Success Rate
4/4 ratings generated profit
100%
Average Return
+52.98%
reiterated a buy rating last month
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +52.98% per trade.
2 Years
xxx
Success Rate
4/4 ratings generated profit
100%
Average Return
+52.98%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +52.98% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MAZE Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
4
4
3
3
4
Buy
1
2
2
2
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
6
5
5
7
In the current month, MAZE has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MAZE average Analyst price target in the past 3 months is 26.75.
Each month's total comprises the sum of three months' worth of ratings.

MAZE Financial Forecast

MAZE Earnings Forecast

The previous quarter’s earnings for MAZE were -$1.15.
The previous quarter’s earnings for MAZE were -$1.15.
No data currently available

MAZE Sales Forecast

The previous quarter’s earnings for MAZE were $0.00.
The previous quarter’s earnings for MAZE were $0.00.

MAZE Stock Forecast FAQ

What is MAZE’s average 12-month price target, according to analysts?
Based on analyst ratings, Maze Therapeutics, Inc.’s 12-month average price target is 26.75.
    What is MAZE’s upside potential, based on the analysts’ average price target?
    Maze Therapeutics, Inc. has 62.61% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MAZE a Buy, Sell or Hold?
          Maze Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Maze Therapeutics, Inc.’s price target?
            The average price target for Maze Therapeutics, Inc. is 26.75. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $34.00 ,the lowest forecast is $17.00. The average price target represents 62.61% Increase from the current price of $16.45.
              What do analysts say about Maze Therapeutics, Inc.?
              Maze Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of MAZE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis